S
Stockadora
Back to Insider Trading View Full Company Profile

RXRX

HEALTHY

RECURSION PHARMACEUTICALS, INC.

CIK: 0001601830

Strong Sell (90% confidence)

Last activity: 1 weeks ago

Financial Metrics

As of Dec 31, 2024 (10-K)

Revenue $44.58M
Net Income -$463.66M
Total Cash $594.35M
Current Ratio 3.81

Insider Roster (4 total, 4 active)

Insider Buys Sells Net Value Holdings
Borgeson Blake
DIRECTOR
 		0 3 -$2.84M
6,429,863 shares
$27.01M
Gibson Christopher
DIRECTOR
 		0 6 -$1.05M
913,839 shares
$3.77M
Khan Najat
Chief R&D Commercial Officer
 		0 1 -$549K
611,135 shares
$2.69M
Taylor Ben R
Chief Financial Officer
 		0 1 -$89K
761,550 shares
$3.18M

Recent Transactions

SELL Gibson Christopher (DIRECTOR)

40,000 shares @ $4.12

$165K

Feb 4, 2026

Conviction: | View SEC Filing →
SELL Borgeson Blake (DIRECTOR)

220,000 shares @ $4.20

$924K

Feb 3, 2026

Conviction: | View SEC Filing →
SELL Gibson Christopher (DIRECTOR)

40,000 shares @ $4.47

$179K

Jan 20, 2026

Conviction: | View SEC Filing →
SELL Borgeson Blake (DIRECTOR)

220,000 shares @ $4.36

$959K

Jan 6, 2026

Conviction: | View SEC Filing →
SELL Gibson Christopher (DIRECTOR)

40,000 shares @ $4.25

$170K

Jan 5, 2026

Conviction: | View SEC Filing →
SELL Taylor Ben R (Chief Financial Officer)

21,383 shares @ $4.18

$89K

Dec 29, 2025

Conviction: | View SEC Filing →
SELL Khan Najat (Chief R&D Commercial Officer)

124,403 shares @ $4.41

$549K

Dec 22, 2025

Conviction: | View SEC Filing →
SELL Gibson Christopher (Chief Executive Officer)

40,000 shares @ $4.50

$180K

Dec 19, 2025

Conviction: | View SEC Filing →
SELL Gibson Christopher (Chief Executive Officer)

40,000 shares @ $4.63

$185K

Dec 4, 2025

Conviction: | View SEC Filing →
SELL Borgeson Blake (DIRECTOR)

220,000 shares @ $4.37

$961K

Dec 2, 2025

Conviction: | View SEC Filing →
SELL Gibson Christopher (Chief Executive Officer)

40,000 shares @ $4.16

$166K

Nov 19, 2025

Conviction: | View SEC Filing →

⚠️ Important Disclaimer

• This is AI-generated analysis for educational purposes only, not financial advice.

• Insider trading data is derived from SEC Form 4 filings and may contain errors.

• Always conduct your own research and consult qualified financial advisors before making investment decisions.